首页 | 本学科首页   官方微博 | 高级检索  
   检索      

阿奇霉素口服治疗小儿呼吸道肺炎支原体感染的临床研究
引用本文:覃州莲,刘志刚,黄小霏,张美品,林业辉.阿奇霉素口服治疗小儿呼吸道肺炎支原体感染的临床研究[J].现代生物医学进展,2014,14(11):2156-2158.
作者姓名:覃州莲  刘志刚  黄小霏  张美品  林业辉
作者单位:广东省佛山市妇幼保健院儿科,广东佛山528000
摘    要:目的:探讨阿奇霉素口服治疗小儿呼吸道肺炎支原体感染的临床效果及安全性。方法:选取2012年5月至2013年10月在我院就诊的144例呼吸道肺炎支原体感染患儿,随机分为观察组和对照组,每组各72例。对照组加用注射用乳糖酸红霉素静滴治疗,观察组加用阿奇霉素口服治疗。对比两组患者的治疗效果及不良反应的发生情况。结果:观察组的总有效率为94.45%,明显高于对照组的83.33%;观察组患儿各临床症状及体征的消失时间均明显短于对照组;观察组患儿不良反应的总发生率为6.95%,显著低于对照组的16.67%,差异均有统计学意义(P0.05)。结论:相比于注射用乳糖酸红霉素静滴治疗,阿奇霉素口服治疗小儿呼吸道肺炎支原体感染疗效更佳,且具有不良反应小,用药安全,患儿的配合度高的优势。

关 键 词:阿奇霉素  红霉素  小儿呼吸道肺炎  支原体感染

Clinical Studies of Oral Azithromycin in the Treatment of Children With Respiratory Tract Infection of Mycoplasma Pneumonia
QIN Zhou-lian,LIU Zhi-gang,HUANG Xiao-fei,ZHANG Mei-pin,LIN Ye-hui.Clinical Studies of Oral Azithromycin in the Treatment of Children With Respiratory Tract Infection of Mycoplasma Pneumonia[J].Progress in Modern Biomedicine,2014,14(11):2156-2158.
Authors:QIN Zhou-lian  LIU Zhi-gang  HUANG Xiao-fei  ZHANG Mei-pin  LIN Ye-hui
Institution:(Department of Pediatric, Foshan Maternity and Child Healthaare Hospital of Guangdong Province, Foshan, Guangdong, 528000, China)
Abstract:Objective: To investigate the clinical efficacy and safety of oral Azithromycin on the treatment of the respiratory tract infection of mycoplasma pneumonia for children. Methods: 144 children with the respiratory tract infection of mycoplasma pneumonia who were treated in our hospital from May 2012 to October 2013 were selected and randomly divided into the observation group and the control group with 72 cases in each one. The patients in the control group were treated by the injection of the intravenous drip Ery- thromycin Lactobionate, while the patients in the observation group were treated by oral Azithromycin. Then the clinical efficacy and ad-verse reactions of patients in the two groups were compared and analyzed. Results: The total effective rate of children in the observation group was 94.45% which was significantly higher than the 83.33% in the control group(P〈0.05). The various clinical symptoms and signs of disappearing time in the observation group were significantly shorter than those of the patients in the control group. The overall inci-dence of adverse reactions in the observation group was 6.95% which was significantly lower than 16.67% in the control group with sta-tistically differences(P〈0.05). Conclusion: It is indicated that the efficacy of oral Azithromycin on the treatment of respiratory tract infec-tion ofmycoplasma pneumonia for children could be better than the injection of the intravenous drip Erythromycin Lactobionate with the advantages of lower incidence of the adverse reactions and more safety for children who were in the high matching degree.
Keywords:Azithromycin  Erythromycin lactobionate  Children with respiratory infection  Mycoplasma infection
本文献已被 CNKI 维普 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号